QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Vol. 15, Issue 4, 1635-1646, April 2004

This Article Full Text Full Text (PDF) All Versions of this Article: E03-07-0506v1 15/4/1635    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiebiger, E. Articles by Tortorella, D. Search for Related Content PubMed PubMed Citation Articles by Fiebiger, E. Articles by Tortorella, D.

Dissection of the Dislocation Pathway for Type I Membrane Proteins with a New Small Molecule Inhibitor, Eeyarestatin

Edda Fiebiger ^*, Christian Hirsch ^*, Jatin M. Vyas , Eva Gordon ^* , Hidde L. Ploegh ^* , and Domenico Tortorella ^* ||

^* Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114

Submitted July 18, 2003; Revised November 13, 2003; Accepted January 5, 2004
Monitoring Editor: Peter Walter

The mammalian endoplasmic reticulum (ER)-to-cytosol degradation pathway for disposal of misfolded proteins is an attractive target for therapeutic intervention in diseases that are characterized by impaired protein degradation. The ability to do so is hampered by the small number of specific inhibitors available and by our limited understanding of the individual steps involved in this pathway. Cells that express a class I major histocompatibility complex (MHC) heavy chain-enhanced green fluorescent protein (EGFP) fusion protein and the human cytomegalovirus protein US11, which catalyzes dislocation of the class I MHC EGFP reporter, show only little fluorescence. Treatment with proteasome inhibitors increases their fluorescence by stabilizing EGFP-tagged MHC class I molecules. We used this change in signal intensity as a readout to screen a chemical library of 16,320 compounds and identified two structurally related compounds (eeyarestatin I and II) that interfered with the degradation of both EGFP-heavy chain and its endogenous unmodified class I MHC heavy chain counterpart. Eeyarestatin I also inhibited degradation of a second misfolded type I membrane protein, T-cell receptor . Both compounds stabilize these dislocation substrates in the ER membrane, without preventing proteasomal turnover of cytosolic substrates. The new inhibitors must therefore interfere with a step that precedes proteasomal degradation. The use of eeyarestatin I thus allows the definition of a new intermediate in dislocation.

Present address: Infinity Pharmaceuticals, 780 Memorial Dr., Cambridge, MA 02139

^|| Present address: Department of Microbiology, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Corresponding author. E-mail address: ploegh{at}hms.harvard.edu.

This article has been cited by other articles:

				Q. Wang, L. Li, and Y. Ye Inhibition of p97-dependent Protein Degradation by Eeyarestatin I J. Biol. Chem., March 21, 2008; 283(12): 7445 - 7454. [Abstract] [Full Text] [PDF]

				W. E. Balch, R. I. Morimoto, A. Dillin, and J. W. Kelly Adapting Proteostasis for Disease Intervention Science, February 15, 2008; 319(5865): 916 - 919. [Abstract] [Full Text] [PDF]

				N. Tolliday, P. A. Clemons, P. Ferraiolo, A. N. Koehler, T. A. Lewis, X. Li, S. L. Schreiber, D. S. Gerhard, and S. Eliasof Small Molecules, Big Players: the National Cancer Institute's Initiative for Chemical Genetics. Cancer Res., September 15, 2006; 66(18): 8935 - 8942. [Abstract] [Full Text] [PDF]

				S. Mukherjee, M. Tessema, and A. Wandinger-Ness Vesicular Trafficking of Tyrosine Kinase Receptors and Associated Proteins in the Regulation of Signaling and Vascular Function Circ. Res., March 31, 2006; 98(6): 743 - 756. [Abstract] [Full Text] [PDF]

				E. Fiebiger, D. Tortorella, M.-H. Jouvin, J.-P. Kinet, and H. L. Ploegh Cotranslational endoplasmic reticulum assembly of Fc{varepsilon}RI controls the formation of functional IgE-binding receptors J. Exp. Med., January 18, 2005; 201(2): 267 - 277. [Abstract] [Full Text] [PDF]